← back to search

Carlos A. Torres‐Cabala

Roswell Park Comprehensive Cancer Center · US
Area of research
Oncology · Dermatology
Research interest
Research interests include Medicine, Lymphoma, Immunotherapy, Nivolumab, Internal medicine, and Oncology.
h-index
citations
2,266
works
10
NIH funding
primary concept
email

Recent publications

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma
Journal of Clinical Oncology 2025cited by 9position: middledoi
Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas
Blood 2025cited by 0position: middledoi
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Nature 2022cited by 326position: middledoi
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2022cited by 161position: middledoi
Clinical and Pathological Characteristics and Outcomes Among Patients With Subcutaneous Panniculitis-like T-Cell Lymphoma and Related Adipotropic Lymphoproliferative Disorders
JAMA Dermatology 2022cited by 33position: middledoi
Severe de novo pustular psoriasiform immune‐related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma
Journal of Cutaneous Pathology 2021cited by 11position: middledoi
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Journal of the National Comprehensive Cancer Network 2020cited by 116position: middledoi
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021
Journal of the National Comprehensive Cancer Network 2020cited by 61position: middledoi
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma
Journal of Investigative Dermatology 2020cited by 22position: middledoi
Prognostic significance of acral lentiginous histologic type in T1 melanoma
Modern Pathology 2020cited by 18position: middledoi
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Cancer Discovery 2015cited by 1,520position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Priyadharsini Nagarajan · The Ohio State University Wexner Medical Center3 papers (2020–2021)Phyu P. Aung · The University of Texas MD Anderson Cancer Center3 papers (2020–2021)Jonathan L. Curry · The University of Texas MD Anderson Cancer Center3 papers (2020–2021)Michael T. Tetzlaff · The University of Texas MD Anderson Cancer Center2 papers (2020–2020)Víctor G. Prieto · Disco (Germany)2 papers (2020–2020)Dirk Schadendorf · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori1 papers (2020–2020)Jennifer A. Wargo · The University of Texas MD Anderson Cancer Center1 papers (2020–2020) · 1 papers (2021–2021)Maria Estela Martínez‐Escala · University of Chicago1 papers (2022–2022)Jaehyuk Choi · Northwestern University1 papers (2025–2025)Pierluigi Porcu · University of Alabama at Birmingham1 papers (2025–2025)Merrick I. Ross · The University of Texas MD Anderson Cancer Center1 papers (2020–2020) · 1 papers (2025–2025)Maya Farah · Boston Medical Center1 papers (2020–2020) · 1 papers (2025–2025)Kenjiro Namikawa · National Cancer Centre Japan1 papers (2020–2020)Linghua Wang · The University of Texas MD Anderson Cancer Center1 papers (2020–2020)Laurence Feldmeyer · University of Lausanne1 papers (2020–2020)Selma Ugurel · Kliniken Essen-Mitte1 papers (2020–2020)Haider A. Mejbel · Emory University1 papers (2020–2020)